August 29, 2018
FDA proposes not including three bulk drug substances that outsourcing facilities may use in compounding
Editor's Note
The Food and Drug Administration (FDA) on August 28 issued a notice proposing not to include three bulk FDA-approved drug substances−bumetanide, nicardipine hydrochloride, and vasopressin−on the list that outsourcing facilities may use in compounding drug products.
The FDA is seeking public comment before finalizing their decision. Comments must be received by October 29, 2018.
Free Daily News
- HFMA warns affordability crisis is driving up provider bad debt
- Report warns sterile processing staffing crisis threatens surgical safety
- Ascension swings to profit as outpatient push, cost cuts take hold
- High BMI alone did not raise early complication risk after outpatient TJA
- AAAHC report spotlights top accreditation deficiencies, strategies for safer ambulatory care
- ACS conference charts bold future for surgical quality with data, teamwork, frontline innovation
- Surgical leaders urged to weigh risks, rewards of innovation with a critical eye
- Health systems report dramatic nurse retention gains through residency, development programs
- Surgical innovation redefines what is possible for advanced colorectal cancer
- CMS proposal to end inpatient only list draws strong industry response
© Access Intelligence, LLC. All rights reserved. |
Privacy Policy |
Cookie Settings |
Diversity, Equity, Inclusion & Belonging |
Accessibility Statement